126 filings
8-K
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
28 Mar 24
Termination of a Material Definitive Agreement
4:05pm
8-K
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
QLGN
Qualigen Therapeutics Inc
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
7 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
n8ut02kf
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
yq54bv2tr0vmetqv1 iz
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
8-K
o8bbez6yn3g0
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
8-K
9m13b 8i29otusu8c3z
17 Oct 23
Regulation FD Disclosure
8:30am
8-K
xs8ih284qj1wgvexq0e
28 Sep 23
Entry into a Material Definitive Agreement
4:15pm
8-K
h3hsfi
15 Aug 23
Results of Operations and Financial Condition
10:04am
8-K
cjh9wa3pqox
4 Aug 23
Departure of Directors or Certain Officers
4:30pm
8-K
inw4tufopt xs
1 Aug 23
Regulation FD Disclosure
8:35am
8-K
bt2m n758
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
8-K
3isugd6 68
13 Jul 23
Submission of Matters to a Vote of Security Holders
5:29pm
8-K
yx8wqxtgkoxji4hww7
26 Jun 23
Departure of Directors or Certain Officers
5:25pm
8-K
0p6jxh6toj4r2oq2wyjd
19 May 23
Departure of Directors or Certain Officers
8:20am
8-K
aacfuvnw1cejsn
5 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
pifqu
24 Apr 23
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
6:15am
8-K
85wspsi0zbsnee
13 Feb 23
Regulation FD Disclosure
9:30am